Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 27.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Celgene Corporation, Eisai, Inc., Genentech, Lilly USA, LLC, and Novartis Pharmaceuticals Corporation.
The optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medical interventions. The multidisciplinary Miami Breast Cancer ConferenceTM has been bringing together surgical, medical, and radiation oncologists for 29 years, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging cross-team cooperation in the clinic. At the 29th Annual Miami Breast Cancer ConferenceTM, pioneers of innovative approaches in each of these subspecialties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.
This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.
Upon completion of the educational activities, participants should be able to:
Discuss how computerization and electronic health record-keeping can be used to improve quality and decrease cost of patient care.
Review recent data from international society meetings and apply practice-changing advances to improve patient care.
Discuss the biologic and molecular pathogenesis of breast cancer development and metastasis, as well as therapeutic implications and strategies for earlier intervention.
Evaluate strategies for the prevention of familial breast cancer and management of hereditary risk, including prophylactic surgery and chemoprevention.
Assess data regarding the optimization of surgery for the treatment of early-stage breast cancer, including controversies in the management of the axilla.
Examine recent advances in radiation therapy for the treatment of patients with breast cancer, and discuss strategies for the individualization of therapy.
Integrate biomarkers, genomic assays, and other risk-assessment tools into treatment decision making for early-stage breast cancer to personalize therapy.
Review the optimal use of bone-modifying agents in patients with early-stage breast cancer or in patients with bone metastases.
Identify appropriate strategies for the use of cytotoxic agents in the treatment of patients with early-stage and advanced/refractory breast cancer.
Discuss standard and novel therapeutic options for patients with HER2-overexpressing breast cancer, including patient selection strategies, combinatorial therapies, and options beyond progression on standard therapy.
Review the rationales for novel targeted agents and innovative treatment regimens, and analyze emerging clinical efficacy and safety data.
Identify and refer eligible patients with breast cancer for promising clinical trials.
You must be logged in to PER to register for this meeting